Jupiter Neurosciences, Inc.
JUNS
$1.11
-$0.13-10.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 372.85% | -17.86% | -61.63% | -50.25% | -63.09% |
| Gross Profit | -372.85% | 17.86% | 61.63% | 50.25% | 63.09% |
| SG&A Expenses | 126.97% | 332.24% | -66.61% | -27.70% | -39.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.49% | 172.29% | -65.78% | -33.19% | -45.52% |
| Operating Income | -169.49% | -172.29% | 65.78% | 33.19% | 45.52% |
| Income Before Tax | -141.11% | -255.59% | 66.69% | 137.61% | 63.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -141.11% | -255.59% | 66.69% | 137.61% | 63.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.11% | -255.59% | 66.69% | 137.61% | 63.71% |
| EBIT | -169.49% | -172.29% | 65.78% | 33.19% | 45.52% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -93.31% | -196.32% | 71.73% | 136.19% | 63.90% |
| Normalized Basic EPS | -93.96% | -177.45% | 67.66% | 26.40% | 41.57% |
| EPS Diluted | -93.31% | -141.50% | 71.43% | 131.75% | 63.90% |
| Normalized Diluted EPS | -93.96% | -177.45% | 67.66% | 34.01% | 41.57% |
| Average Basic Shares Outstanding | 24.80% | 19.71% | 17.66% | 4.30% | 0.57% |
| Average Diluted Shares Outstanding | 24.80% | 19.71% | 17.66% | 15.87% | 0.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |